merged_eli-lilly-zepbound-price.txt
<other>I need to analyze the article about Eli Lilly's Zepbound vials and answer each question based solely on the information provided in the text.</other>

<question_number>1</question_number>
<answer>Lilly is positioning its vials as a safer option than compounded drugs, which are subject to far less oversight than traditionally approved medications</answer>

<question_number>2</question_number>
<answer>LillyDirect offers online prescriptions and direct delivery to patients' doors, similar to telehealth companies, while providing FDA-approved medications at competitive prices</answer>

<question_number>3</question_number>
<answer>Compounded drugs are subject to far less oversight than traditionally approved medications and are not controlled for safety, quality and effectiveness</answer>

<question_number>4</question_number>
<answer>It allows Lilly to compete with compounded alternatives that cost between $250-$450 per month and regain customers who switched to those cheaper options</answer>

<question_number>5</question_number>
<answer>When tirzepatide is removed from the FDA shortage list, there should be no legal space for mass compounders to produce copycat versions</answer>

<question_number>6</question_number>
<answer>Lilly can offer "transparent pricing" by selling directly and "removing third-party supply chain entities"</answer>

<question_number>7</question_number>
<answer>The appeal to people on Medicare could be concerning since Medicare doesn't cover weight-loss medications and the drugs carry unique risks for older patients including muscle loss</answer>

<question_number>8</question_number>
<answer>By positioning FDA-approved vials as safer alternatives to compounded drugs that lack proper oversight and safety controls</answer>

<question_number>9</question_number>
<answer>Tirzepatide is listed by the FDA as "in shortage"</answer>

<question_number>10</question_number>
<answer>Lower pricing to signal to the telehealth space that Lilly will get market share back from them</answer>